ArticleJournal of medicinal chemistry2010
Bivalent diketopiperazine-based tropomysin receptor kinase C (TrkC) antagonists.
Article in Journal of medicinal chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Selective Modulation of Trk Receptors byACS chemical neuroscience · 2025Article
- Selective inhibitors of the TrkC.T1 receptor reduce retinal inflammation and delay neuronal death in a model of retinitis pigmentosa.PNAS nexus · 2025Article
- Selective, Intrinsically Fluorescent Trk Modulating Probes.ACS chemical neuroscience · 2024Article
- Cyclic Dipeptides: The Biological and Structural Landscape with Special Focus on the Anti-Cancer Proline-Based Scaffold.Biomolecules · 2021Review
- Microwave-assisted facile construction of quinoxalinone and benzimidazopyrazinone derivatives via two paths of post-Ugi cascade reaction.Molecular diversity · 2019Article
- Neuroprotection: Pro-survival and Anti-neurotoxic Mechanisms as Therapeutic Strategies in Neurodegeneration.Frontiers in cellular neuroscience · 2019Review
- Cyclic cis-Locked Phospho-Dipeptides Reduce Entry of AβPP into Amyloidogenic Processing Pathway.Journal of Alzheimer's disease : JAD · 2017Article
- Targeted PDT agent eradicates TrkC expressing tumors via photodynamic therapy (PDT).Molecular pharmaceutics · 2015Article
- Combinatorial assembly of small molecules into bivalent antagonists of TrkC or TrkA receptors.PloS one · 2014Article
- Developing bivalent ligands to target CUG triplet repeats, the causative agent of myotonic dystrophy type 1.Journal of medicinal chemistry · 2013Article
- The diketopiperazine-fused tetrahydro-β-carboline scaffold as a model peptidomimetic with an unusual α-turn secondary structure.Beilstein journal of organic chemistry · 2013Article
- Low molecular weight, non-peptidic agonists of TrkA receptor with NGF-mimetic activity.Cell death & disease · 2012Article
- Design, synthesis, and validation of a β-turn mimetic library targeting protein-protein and peptide-receptor interactions.Journal of the American Chemical Society · 2011Article
- Diastereoselective synthesis of diketopiperazine bis-α,β-epoxides.The Journal of organic chemistry · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Bivalent molecules containing two beta-turn mimics with side chains that correspond to hot-spots on the neurotrophin NT-3 were prepared. Binding assays showed the mimetics to be selective TrkC ligands, and biological assays showed one mimetic to be an antagonist of the TrkC receptor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.